HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

1-800 Pharmacy “Clinically Proven” Claims Should Be Modified – ERSP

This article was originally published in The Rose Sheet

Executive Summary

1-800 Pharmacy should modify claims that its OHT Peptide-3 is "clinically proven" to reduce wrinkles, the Electronic Retailing Self-Regulation Program said

You may also be interested in...



Skin Care Marketers’ Anti-Aging Claims Keep NAD, ERSP Busy In ’05

Anti-aging skin care claims dominated inquiries into cosmetics and personal care advertising by watchdog groups in 2005

Skin Care Marketers’ Anti-Aging Claims Keep NAD, ERSP Busy In ’05

Anti-aging skin care claims dominated inquiries into cosmetics and personal care advertising by watchdog groups in 2005

ERSP

DermaRadiant should discontinue claims that its Anti-Wrinkle Complex is "clinically proven" to improve appearance of wrinkle depth in direct-response marketing since testing of the product did not produce statistically significant results, according to Electronic Retailing Self-Regulation Program. However, the study did support general efficacy claims, watchdog group says in recent decision. ERSP also recommended DermaRadiant discontinue implied comparative claims referencing plastic surgery, such as "No Risk Injections. No Costly Doctor Visits and Prescriptions. No Painful Surgery." In a separate case, ERSP requested DermaRadiant discontinue testimonials for Ageless Eyes that product offers immediate results. Group found various performance claims for the formula were supported by clinical studies...

Related Content

UsernamePublicRestriction

Register

RS013408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel